- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00703066
Safety and Immunogenicity of 30 and 100 µg of GMZ2 in Gabonese Children Aged 1-5 Years
A Phase I, Randomized, Controlled, Double-Blind, Single Centre Trial to Evaluate the Safety and Immunogenicity of 30 and 100 µg of GMZ2 in Gabonese Children Aged 1-5 Years
The study aims to show that the candidate malaria vaccine GMZ2 is as safe as the already publicly used vaccine against rabies. 30 Gabonese children aged 1-5 years will be enrolled and randomly allocated to receive either malaria vaccine or rabies vaccine without the investigator or the participants knowing what they received. They will receive 3 doses each at one month intervals, and will be followed up for one year to evaluate safety parameters. 30 and 100µg doses for the candidate malaria vaccine GMZ 2 will be evaluated for safety.
This is the second time that candidate malaria vaccine GMZ 2 is being tested in Africa, the first time being in Gabonese adults where the product was found to be safe.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background. GMZ2 is a recombinant hybrid of the Glutamate Rich Protein (GLURP) and the Merozoite Surface Protein 3 (MSP 3).This product has been developed at State Serum Institute/EMVI in Denmark and Batch released by Henogen of Belgium. The phase Ia trial in malaria naive volunteers was done in Germany, at Tuebingen University. This phase Ia trial established safety of the vaccine and also assisted in selecting the best dosage (10, 30 or 100 µg). The dosage with the best safety and immunogenicity profile will be tested for the phase Ib trials in Gabon, including this phase Ib trial in children.
Objectives:
Primary objective:
To evaluate the safety and reactogenicity of three doses of 30 and 100µg GMZ2, adsorbed on aluminium hydroxide, in comparison with three doses of the control vaccine (rabies), in healthy Gabonese children aged 1-5 years.
Secondary objectives:
To assess the humoral immune response to the vaccine antigens GMZ2, GLURP and MSP3 by measuring the total IgG concentration and IgG isotypes against GMZ2 by ELISA.
To assess B-cell memory by memory B-cell ELISPOT.
Exploratory Objectives:
To assess the functionality of the immune response by measuring the Growth Inhibition of P. falciparum in the presence or absence of Monocytes, and by measuring the recognition of native antigen of P. falciparum by IFA.
Study Design:
Phase Ib double-blind, randomised, and controlled trial with three groups at one study site; rabies vaccine,30µg and 100 µg GMZ 2 vaccine.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Lambarene, Gabon
- Medical Research Unit, Albert Schweitzer Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Children age 1-5 years inclusive at the time of screening;
- Residing in Lambaréné for the duration of the study;
- Written informed consent obtained before screening and study start, respectively;
- Available to participate in follow-up for the duration of study (13 months);
- General good health based on history and clinical examination.
Exclusion Criteria:
- Previous vaccination with any other malaria candidate vaccine.
- Concomitant vaccination with a investigational vaccine or a rabies vaccine;
- Use of a investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the first study vaccination, or planned use up to 30 days after the third vaccination;
- Chronic administration (defined as more than 14 days) of immuno-suppressants or other immune-modifying drugs within six months prior to the first vaccination. This includes any dose level of oral steroids or inhaled steroids, but not topical steroids;
- Confirmed or suspected immunosuppressive or immuno-deficient condition, including human immunodeficiency virus (HIV) infection;
- Confirmed or suspected autoimmune disease;
- History of allergic reactions or anaphylaxis to immunizations or to any of the vaccine components, or of serious allergic reactions to any substance, requiring hospitalization or emergent medical care;
- History of splenectomy;
- Laboratory evidence of liver disease (Alanine aminotransferase [ALT] greater than 1.25 times the upper limit of normal (<45 U/L) of the testing laboratory);
- Laboratory evidence of renal disease (serum creatinine greater than the upper limit of normal of the testing laboratory, or more than trace protein or blood on urine dipstick testing);
- Laboratory evidence of haematological disease (absolute leukocyte count 3.5-11/µL, absolute lymphocyte count 560-5280/µL, platelet count 120,000-400,000/µL, or haemoglobin 10.0-16.5g/dL);
- Administration of immunoglobulins and/or any blood products within the three months preceding the first study vaccination or planned administration during the study period;
- Simultaneous participation in any other interventional clinical trial;
- Acute or chronic pulmonary, cardiovascular, hepatic, renal or neurological condition, malnutrition, or any other clinical findings that in the opinion of the clinical investigator, may increase the risk of participating in the study;
- Other condition that in the opinion of the clinical investigator would jeopardize the safety or rights of a participant in the trial or would render the participant unable to comply with the protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
three doses of 30µg GMZ2,
|
three doses of 30µg of GMZ 2 vaccine,
100 µg of GMZ 2 vaccine
|
Experimental: 2
3 doses of 100 µg of GMZ2
|
three doses of 30µg of GMZ 2 vaccine,
100 µg of GMZ 2 vaccine
|
Active Comparator: 3
Rabies vaccine
|
3 doses of Rabies vaccine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Occurrence of serious adverse events
Time Frame: 1 year
|
1 year
|
Biological safety
Time Frame: 1 year
|
1 year
|
Immediate reactogenicity.
Time Frame: within 30 minutes after each injection
|
within 30 minutes after each injection
|
Local and systemic reactogenicity
Time Frame: 14 days following each immunization
|
14 days following each immunization
|
unsolicited Adverse events
Time Frame: up to 1 month after the 3rd vaccination
|
up to 1 month after the 3rd vaccination
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Humoral immune response to GLURP and MSP 3
Time Frame: 1 year
|
1 year
|
Cellular immune response
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Peter Kremsner, MD, PhD, Medical Research Unit, Albert Schweitzer Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GMZ2_3_08
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...Completed
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute...CompletedPlasmodium Falciparum Malaria | Uncomplicated Malaria | Malaria FeverNigeria
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationCompletedTES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014 (TES)Malaria | Vivax Malaria | Falciparum Malaria | Malaria Recrudescence
Clinical Trials on GMZ 2 vaccine (GLURP + MSP 3)
-
African Malaria Network TrustLondon School of Hygiene and Tropical MedicineUnknownMalariaBurkina Faso
-
African Malaria Network TrustLondon School of Hygiene and Tropical MedicineUnknown
-
Sinovac Research and Development Co., Ltd.Active, not recruiting
-
China National Biotec Group Company LimitedBeijing Institute of Biological Products Co Ltd.Active, not recruiting
-
National Vaccine and Serum Institute, ChinaBeijing Institute of Biological Products Co Ltd.; Lanzhou Institute of Biological...Active, not recruiting
-
National Institute of Allergy and Infectious Diseases...Completed
-
Sanofi Pasteur, a Sanofi CompanyTerminatedCOVID-19United States, Australia, Brazil, Honduras
-
Guangxi Zhuang Autonomous Region Center for Disease...Air Force Military Medical University, China; Beijing Tiantan Biological Products...Completed
-
Meissa Vaccines, Inc.Recruiting
-
NewLink Genetics CorporationCompleted